About Us

Evogene is a leading computational biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology (‘CPB’) platform.

The ‘CPB’ platform has been designed for the in-silico prediction and prioritization of genes, microbes and small molecules based on multiple attributes that will be key to successful development and commercialization of novel life-science based products.

Successfully addressing these multiple product attributes at the beginning of the development process, ‘stage zero’, rather than one at a time, is expected to reduce the time and cost of product development, and much more importantly, increase the probability of a successful outcome.

Following such in-silico prediction and prioritization, the resulting candidates are experimentally validated in lab and greenhouse testing or other biological/chemical assays. Furthermore, the nature of the prediction/experimentation process results in the CPB’s accuracy continuously improving with each use.

The CPB platform is utilized to generate novel products in market segments with product development roadblocks that can be addressed by it. Today, the platform is implemented in three general life-science based markets: agriculture, human health and life-science based industrial applications.

In order to capture the value of the CPB platform we established a corporate structure where Evogene and the CPB platform are at the heart of all activities with a group of divisions and subsidiaries each focused in different life-science based markets that have exclusive access to the CPB platform for their field of activity, providing their main competitive advantage for their product development pipeline.

Currently, the subsidiaries and divisions include the following activities:

In the field of agriculture:

  • AgPlenus Ltd., focusing on the development of novel herbicides and insecticides,
  • Lavie-bio Ltd., focused on bio-stimulants and bio-pesticides and
  • Ag-Seeds division, focusing on (a) insect control seed traits, (b) yield & abiotic stress and (c) disease resistance seed traits, the former two utilizing both GMO and non-GMO approaches.

In the human health field:

  • Biomica Ltd., focused on developing therapeutics based on microbes and small molecules in the areas of immuno-oncology, multi drug resistant organisms and GI related disorders.
  • Canonic Ltd., focusing on developing medical grade cannabis products through a plant genomic approach.

In the broad field of life-science based industrial markets:

  • Casterra Ltd., formerly Evofuel, focused on the development an integrated ag-solution to address the growing global demand for stable castor oil supply.

The Company’s headquarters are located in Rehovot, Israel and is listed for trading on the NASDAQ (NASDAQ: EVGN) and on the Tel Aviv Stock Exchange (TASE: EVGN).

    • Mr. Ofer Haviv

      Mr. Ofer Haviv

      President and Chief Executive Officer

      Ofer Haviv holds the position of Evogene’s President and CEO as of late 2004. Prior to that he held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene’s spin-off from Compugen in 2002. At Compugen, he held the position of Director of Finance and Treasurer of Compugen (NASDAQ: CGEN) for four years, during which time the company completed two private placements and an IPO on NASDAQ

      Mr. Haviv holds a B.A. degree in Economics and Accounting from Faculty of Management, Tel Aviv University and is a Certified Public Accountant in Israel.


    • Mr. Mark Kapel

      Mr. Mark Kapel

      Executive Vice President Technology

      Mark was appointed as Executive Vice President Technology in February 2018, previously serving as Director of Information Technologies & Data Management from 2013. Mr. Kapel joined Evogene in 2005 and has held various positions in the company over the years.

      Mr. Kapel holds a B.Sc. in Physics & Computers from the Ben Gurion University of Negev, an MBA majoring in Management of Technology from Tel Aviv University’s Faculty of Management – Recanati Graduate School of Business Administration.



    • Ms. Dorit Kreiner

      Interim Chief Financial Officer

      Ms. Dorit Kreiner was appointed Interim CFO in February 2019, bringing over 20 years of senior financial management experience. She previously served as Chief Financial Officer in Therapix (TASE: THXBY) and NRGene. In addition, Ms. Kreiner served as Director of Finance of Evogene from June 2004 through August 2011.

      Ms. Kreiner holds a BA in accounting and economics and an MBA in Finance and Marketing, both from Tel Aviv University, and a Bachelor of Law from the College of Management.



    • Dr. Eyal Emmanuel

      Chief Scientific Officer

      Dr. Emmanuel serves as Evogene’s CSO since February 2019. Dr. Emmanuel rejoined Evogene as VP of Corporate Strategy in September 2018, previously held several R&D positions in the Company from May 2006 through October 2017, including Executive R&D Crop Protection and Chief Science Officer.

      Dr. Emmanuel holds a Ph.D. from the Weizmann Institute of Science, and an MBA from the College of Management.


    • Mr. Martin Gerstel, Chairman

      Martin Gerstel  is Chairman of Keddem Bioscience, a privately owned drug discovery company and Co-Chairman of Itamar Medical, a publicly owned medical device company. Mr. Gerstel currently serves as senior advisor to the Chairman of the Board of Directors of Compugen Ltd. a publicly owned drug and diagnostic discovery company and until recently held the position of Chairman of Compugen Ltd. These companies are all headquartered in Israel. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a pharmaceutical company based on advanced drug delivery.

      In addition, Mr. Gerstel currently serves as a director of YEDA Technology Transfer, Yissum Technologies and the Foundation for the US National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and to the Board of the Israel-U.S. BiNational Industrial Research and Development (“BIRD”) Foundation.

      Mr. Gerstel is a graduate of Yale University and the Stanford Graduate School of Business.

    • Ms. Sarit Firon

      Ms. Sarit Firon serves as a managing partner of Cerca Partners, a venture capital investment fund, since 2016, where she previously served in the investment committee since 2014. In addition, Ms. Firon serves as chairperson of the board of directors of myThings, an ad-tech company, since 2015 and as a director in the following companies: DATORAMA, a marketing analytics company, since 2012; MediWound, a biotechnology company, since 2014; and Extreme Reality, a 3D motion capture gaming technology company, between 2014 – May 2016. Prior to that, Ms. Firon served as CEO of Extreme Reality from 2012 to 2014 and in several CFO positions since 1997 in Kenshoo, MediaMind, Olive Software, P-Cube, and RadCom.

      Ms. Firon holds a B.A. in accounting and economics from Tel-Aviv University.

    • Mr. Ziv Kop

      Ziv Kop is the Chief Operating Officer and member of the Board of Directors of Outbrain Inc. a web-based  content discovery platform, as well as a director of Kamada Ltd (NASDAQ:KMDA).

      Previously, and since its inception in 2003 until June 2013, Mr. Kop was a Managing Partner at GlenRock Israel, a private equity investment firm, where he managed a portfolio of growth companies in the fields of advanced technologies and healthcare, and served on the board of more than ten private and public companies.

      Prior to his role at GlenRock, Mr. Kop served as Chief Executive Officer of POC Management Consulting, a leading Israeli consultancy in the field of strategic planning.

      Mr. Kop holds an LLB and MBA from Tel Aviv University Law School and Business School, and is a graduate of INSEAD’s Young Managers Program.

    • Dr. Adrian Percy

      Dr. Percy joined Evogene’s board of directors in February 2019.

      Dr. Percy has more than 25 years of experience in the agricultural industry and most recently served as Head of Research & Development for the Crop Science division of Bayer and member of its Executive Committee. In this position, he had responsibility for Bayer’s activities in the areas of crop protection chemistry and biologicals, as well as seeds and traits, including regulatory affairs activities. Previously he held numerous positions in the research and development departments of Rhone Poulenc, Aventis CropScience and Bayer in France, Germany and the United States.

      Dr. Percy holds a Bachelor’s degree in Pharmacology from the University of Liverpool, and a Master’s degree in Toxicology and doctorate in Biochemistry, both from the University of Birmingham.

    • Mr. Leon Recanati

      Mr. Leon Recanati is the founder and CEO of GlenRock Israel, a private equity group. Mr. Recanati was Chairman and CEO of IDB Holding Corporation, one of the largest investment groups in Israel until May 2003. In addition, he served as Chairman of Clal Industries and Investments, Discount Investment Corporation, and Azorim Investment Development and Construction. Mr. Recanati was Chairman of Delek Israel Fuel Corporation and Super-Sol until 1997, in addition to several other positions in a variety of operating companies in Israel.

      Mr. Recanati’s personal involvement in organizations and diverse causes has earned him a reputation as one of Israel’s outstanding community leaders. He is Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association and Chairman of Tel-Aviv University’s Development Committee. He is also an active member of the Board of Governors of Tel-Aviv University and the Hebrew University of Jerusalem, The Technion Israel Institute of Technology, The Jewish Agency, and Chairman of Tapuah – The Israeli Society for the Advancement of the Information Age.

      Mr. Recanati received his BA and MBA degrees from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and Tel-Aviv University.

    • Prof. Oded Shoseyov

      Prof. Shoseyov is a world renowned scientist and a faculty member of the Hebrew University of Jerusalem. Prof. Shoseyov conducts research in plant molecular biology protein engineering and nano-biotechnology. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002, the Kay Award for Innovative and Applied Research in 1999 and 2010, and the 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. He is the scientific founder of 12 companies, including Futuragene and Collplant.

    • Prof. Avraham Levy, Chairman of the scientific advisory board

      Prof. Avraham Levy is the Head of the Plant Science Department of the Weizmann Institute of Science in Rehovot, Israel. Prof. Levy heads a laboratory studying mechanisms that contribute to the accelerated evolution of plant genomes, such as transposons, DNA damages, DNA recombination and genome duplications. He works on wheat, Arabidopsis tomato and budding yeast. Prof. Levy is the president of the Genetic Society of Israel, he served as the chairman of the Israeli Graminae consortium and on several national and international granting agencies panels. He is an ERC fellow and has lead scientific projects as coordinator for an EU consortium and for an Israeli Center of Research Excellence.

      Prof. Levy holds a B.Sc. and an M.Sc. degree from the Faculty of Agriculture of the Hebrew University of Jerusalem and a Ph.D. from the Department of Plant Genetics of the Weizmann Institute of Science. His post-doctoral research was done at Stanford University.

    • Prof. James Birchler

      Prof. James Birchler is Curators’ Professor of Biological Science at the University of Missouri, Columbia.  He joined the University of Missouri in 1991 after serving as an associate professor at the Harvard University since 1985. Prof. Birchler lab’s research interests include gene expression in polyploids of maize, the molecular basis of aneuploid syndromes and of heterosis, the structure and behavior of chromosomes and centromeres in maize, the construction of engineered minichromosomes and in general the consequences of dosage-sensitive gene regulatory mechanisms in multicellular eukaryotes.

      Prof. Birchler received his PhD in genetics and biochemistry in 1977 from Indiana University, where he studied dosage effects on gene expression in maize. His postdoctoral work was done at Oak Ridge National Lab, Roswell Park Memorial Institute, and the University of California, Berkeley. He is a fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Sciences (USA).

    • Prof. Naama Barkai

      Prof. Naama Barkai is a professor in the departments of Molecular Genetics and Physics of Complex Systems at the Weizmann Institute of Science in Rehovot, Israel and a member of of the European Molecular Biology Organization (EMBO), the European Bioinformatics Institute (EBI), the ERC Starting Grant evaluation panel, the European Molecular Biology Laboratory (EMBL), Academia Europaea, and of the Israel Academy of Sciences and Humanities.

      Prof. Naama Barkai received her PhD in Theoretical Physics in 1995 from the Hebrew University where she Graduated Summa Cum Laude in the studies of Statistical Mechanicsof Learning“. Her Post-Doctoral Fellow at the Physics Department, Princeton University in Princeton, New Jersey focused on Theoretical Study of Biochemical Networks.

      Prof. Barkai lab research is focused at the interface between mathematics and biology and understanding the biological constraints that are imposed on a particular system, and the impact of those constraints on the structural design of the network while developing novel solutions for fundamental biological problems such as nutrient homeostasis systems  and the organization of the cellular transcription programs.

    • Prof. Angela Sessitsch

      Dr. Angela Sessitsch heads the Bioresources Unit of the AIT Austrian Institute of Technology and is currently the President of the Austrian Association of Molecular Life Sciences and Biotechnology. The group of Dr. Sessitsch is interesting in understanding and exploring plant-associated microbiomes, primarily microbial endophytes. Her group is interested in understanding the ecology and functioning of plant microbiomes as well as to address application-relevant aspects. She has been leading national and international EU research projects and has recently initiated the EPSO Working Group on Plants and Microbiomes.

      Dr. Sessitsch holds a M.Sc. from the University of Technology, Graz, Austria and received her Ph.D. in 1997 from the Wageningen University, Netherlands. She is habilitated at the Vienna University of Natural Resources and Life Sciences. Dr. Sessitsch worked for several years with the United Nations (IAEA and FAO) before she joined AIT.

    • Dr. Hansjoerg Kraehmer

      Hansjoerg Kraehmer was born as the son of a farmer near Ulm, Germany, in 1951.

      He studied biology, chemistry and physics in Hohenheim and in Heidelberg. He received his PhD from Heidelberg University in the year 1979 and joined Schering AG in Berlin as a biologist in Research. He became department head of Herbicide Biology in the year 1986. Shortly after the formation of Hoechst-Schering Agrevo GmbH, he moved to Wilmington, DE, where he spent 2 years as Visiting Director Market Development. Back in Frankfurt, he worked for two years as a marketing manager. As a member of Aventis Crop Science GmbH, he established a robot based high throughput screening in the year 2000 together with around 20 scientists and technicians. He ended his active career within Bayer CropScience as head of Profiling and Product Support. H. Kraehmer published more than 50 papers, several book chapters and two scientific books.  He filed more than 30 patents. He was president of the European Weed Science Society between 2010 and 2012. Also, he was managing board member of the Wirtschaftsverbund Pflanzengenomforschung GABI e.V. (WPG) between 2007 and 2012. In 2015, he became member of the Editorial Board of Scientia Agriculturae Bohemica. For the last three years he worked as a consultant for different organisations.

  • As part of Evogene’s commitment to contribute to the community in which it operates, the company sees great value in its involvement and the involvement of its employees in the community, with a focus on populations in-need. In addition, as a company in the biotech industry, which requires higher scientific education, Evogene sees value in contributing the educational advancement of disadvantaged students through financial support to promote this purpose.

    Evogene’s CSR activity is focusing on three main areas:

    • Diversity in human resources
    • Academic support of disadvantaged students in the field of plant sciences
    • Social involvement in the community through volunteering activities, in which company employees take an active role

    Evogene’s past years and current CSR activities include cooperation with ‘SHEKULO TOV’ association which provides a variety of employment and leisure initiatives to hundreds of disabled people in order to facilitate their integration in the community; and with ‘MESHI’- Rehovot, a rehabilitation center which integrates people with mental disability in the labor market. The cooperation includes integration of individuals from these organizations in the company’s on-going operation.

    Furthermore, company employees are involved in volunteering activities during the Israeli holidays to collect, pack and provide food packages for populations in-need. The volunteering activities are conducted in cooperation with ‘Hod Israel’, a community charity organization, and ‘Latet’, an Israeli humanitarian aid organization.